ApconiX Company News Archives
ApconiX Welcomes Dr Kerry Illston ApconiX is delighted to welcome Dr Kerry Illston who joins the team of nonclinical safety experts and will be working with Dr Richard Knight. Kerry is an experienced Project Manager with over 25 years’ experience in molecular toxicology, new target identification/validation and nonclinical safety [...]
Queen's Award Celebration On Tuesday the 6th of September Lady Redmond, Lord Lieutenant of Cheshire came to Alderley Park to present ApconiX with the Queen’s Award for Enterprise in recognition of excellence in international trade. Lady Redmond, accompanied by Sir Philip Redmond, presented the certificate to the directors and co-founders Dr Richard Knight, [...]
ApconiX Welcomes Michelle Blissett ApconiX is delighted to welcome Michelle Blissett who joins the Acuity Target Safety Assessment team working with Professor Ruth Roberts and Dr James Sidaway. With almost 20 years devoted to preclinical toxicology, Michelle has developed an excellent ability to conduct extensive literature searches, interrogating, analysing [...]
ApconiX Welcomes William Humfrey ApconiX is delighted to welcome William Humfrey who joins the Acuity Target Safety Assessment team working with Professor Ruth Roberts and Dr James Sidaway. Will studied for an integrated master’s degree in biomedical science at the University of Sheffield where he gained understanding of human [...]
Platelet Function Testing in Target Safety Assessments Adverse Findings Adverse findings in non-clinical safety/toxicity testing continue to be a major reason for failure and/or complexity in drug projects. Since primary target-related toxicity plays a role in a significant proportion of these failures, an in-depth assessment of potential adverse consequences [...]
ApconiX Welcomes Esther McVey MP We were delighted to welcome Esther McVey MP for Tatton to ApconiX on Friday 12th of August. She congratulated us on our recent success with the Queen’s Award for Enterprise having been recognised for excellence in International Trade. We shared with her our ambitions around [...]
ApconiX is Delighted to Welcome Henry Bushell ApconiX is delighted to welcome Henry Bushell who joins the Business Development team and is working with Dr Laurence Bishop. Henry has a keen interest in economics and decided to acquire some business experience, joining ApconiX straight from sixth form college. Taking [...]
Minister for Exports Congratulates ApconiX Minister for Exports, Mike Freer congratulated ApconiX for being honoured with the Queen's Award for Enterprise. The three Directors and Co-founders, Dr Richard Knight, Dr Michael Morton and Professor Ruth Roberts are all delighted that their hard work and determination and that of the whole team at ApconiX has [...]
Unravelling Some Mechanistic and Clinical Aspects of Immunological Drug-Drug Interactions Dr Sean Hammond, as a member of an interdisciplinary team, has recently published the third of a series of papers seeking to unravel mechanistic and clinical aspects of the immunological drug-drug interactions that occur with immune checkpoint inhibitors. Immunotoxicology [...]
The Importance of "Agility" Post COVID In 2021, we shared our whole-hearted agreement with the 2020 Forbes Article describing agility as the new superpower. Agility certainly allowed ApconiX to thrive and grow during the pandemic by focusing on the science and on people rather than on any pre-existing plans or process, allowing our [...]
